Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Scientists from Malvern Instruments and Novozymes Biopharma have completed the first phase of collaborative studies, evaluating the formulation stability of two recombinant albumins.
Subscribe to our email newsletter
According to Pharmabiz, the studies involved the application of Malvern’s light scattering technologies in evaluating the formulation stability of Albucult and Recombumin.
The teams applied the resolving capabilities of size exclusion chromatography light scattering and dynamic light scattering offered by Malvern’s Zetasizer Nano system to monitor the stability of Novozymes products.
Novozymes customer solution specialist Mark Perkins said that the Malvern systems have proved highly effective in this application, allowing the company to further demonstrate the stability and purity of its products.